Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716799 | 0.88 | ROCK2 (0.76) | POLA1ROCK2MAPTPOLBGAA | |
| SCHEMBL10036308 | 0.88 | ROCK2 (0.76) | POLA1ROCK2MAPTPOLBGAA | |
| SCHEMBL5253850 | 0.85 | POLA1 (0.57) | POLA1ROCK2MAPTPOLBGAA | |
| SCHEMBL14340751 | 0.82 | POLA1 (0.53) | POLA1ROCK2MAPTPOLBGAA | |
| SCHEMBL13115515 | 0.80 | ROCK2 (0.53) | POLA1ROCK2MAPTPOLBGAA | |
| SCHEMBL3364603 | 0.78 | ROCK2 (0.56) | POLA1ROCK2MAPTPOLBGAA | |
| SCHEMBL10036350 | 0.76 | ROCK2 (0.79) | POLA1ROCK2MAPTKMT2ACYP3A4 | |
| SCHEMBL6396934 | 0.74 | ROCK2 (1.00) | ROCK2CYP3A4AGPAT2ROCK1 | |
| SCHEMBL5254355 | 0.74 | ROCK2 (1.00) | ROCK2MAPTCYP3A4NPC1CYP1A2 | |
| SCHEMBL10036351 | 0.74 | ROCK2 (0.79) | POLA1ROCK2MAPTCYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | POLA1 3367/4885ROCK2 3/4885MAPT 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.